TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Levetiracetam or Pregabalin in Treating Seizures in Patients Undergoing Chemotherapy and/or Radiation Therapy For Primary Brain Tumors

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of primary brain tumor~  * WHO grade II-IV disease~* Undergoing chemotherapy and/or radiotherapy~* No brain tumor without the potential need for chemotherapy (e.g., meningioma without anaplastic features)~* Has had at least one seizure provoked by the brain tumor, justifying introduction of antiepileptic drug (AED) treatment~  * No status epilepticus~PATIENT CHARACTERISTICS:~* Modified Rankin score \< 4 at study enrollment~* Life expectancy ≥ 4 weeks~* Not pregnant~* Negative pregnancy test~* Fertile patients must use effective contraception~* No known intolerance to the study drugs~* No pre-existing psychosis and/or current suicidality~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* No concurrent IV AEDs other than benzodiazepines~* Other concurrent AEDs, except phenobarbital, allowed provided they are discontinued within 2 weeks after study enrollment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Levetiracetam (Type: ACTIVE_COMPARATOR): Patients assigned to Levetiracetam are treated with the initial dose of 2 x 250mg per day up to one year
- Pregabalin (Type: ACTIVE_COMPARATOR): Patients assigned to Pregabalin are treated with the initial dose of 2 x 75mg per day up to one year

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: House Dust Mite Allergy Trial In Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects aged 5-11 years~* A clinical history of HDM AR/C (Allergic rhinitis/rhinoconjunctivitis) (with or without asthma) and with allergic rhinitis symptoms despite having received allergy pharmacotherapy during the previous year prior to screening~* Have a certain level of AR (Allergic rhinitis) symptoms on at least 8 of the last 14 days of the baseline period~* Use symptomatic medication for treatment of HDM allergic rhinitis during at least 8 of the last 14 days of the baseline period~* Positive skin prick test (SPT) and IgE (Immunoglobulin E) to D. pteronyssinus or D. farinae at screening~* Lung function ≥ 70% of predicted value~Exclusion Criteria:~* Sensitised and regularly exposed to perennial allergens~* Any nasal or pharyngeal condition that could interfere with the safety or efficacy evaluation~* Asthma requiring treatment with high dose of inhaled corticosteroid~* A relevant history of systemic allergic reaction

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 11 Years
- Healthy Volunteers: f

Study Arms:
- Active treatment (Type: EXPERIMENTAL): HDM SLIT-tablet plus allergy and asthma rescue medication
- Placebo (Type: PLACEBO_COMPARATOR): Placebo oral tablet plus allergy and asthma rescue medication

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Using Vedolizumab-800CW to Gain Insight Into Local Drug Distribution and Mucosal Target Cells in IBD Patients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Established diagnosis of IBD, or Ulcerative Colitis (UC) or Crohn's Disease (CD).~* Vedolizumab naïve and eligible for vedolizumab treatment.~* Age: 18 years or older.~* Written informed consent.~Exclusion Criteria:~* Prior vedolizumab treatment~* Vedolizumab contraindicated as therapy~* Pregnancy or breast feeding.~* Patients younger than 18 years old

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- No administration of vedolizumab-800CW (Type: OTHER): Patients did not receive vedolizumab-800CW but underwent a Fluorescence molecular imaging procedure to serve as a control group and compare results with patients receiving the tracer
- 4.5 mg vedolizumab-800CW group (Type: EXPERIMENTAL): Patients received 4.5 mg vedolizumab-800CW and subsequently underwent a Fluorescence molecular imaging procedure
- 15 mg vedolizumab-800CW group (Type: EXPERIMENTAL): Patients received 15 mg vedolizumab-800CW and subsequently underwent a Fluorescence molecular imaging procedure
- 75 mg vedolizumab + 15 mg vedolizumab-800CW group (Type: EXPERIMENTAL): Patients received 75mg vedolizumab + 15 mg vedolizumab-800CW and subsequently underwent a Fluorescence molecular imaging procedure
- 300mg vedolizumab + 15mg vedolizumab-800CW group (Type: EXPERIMENTAL): Patients received 300mg vedolizumab + 15 mg vedolizumab-800CW and subsequently underwent a Fluorescence molecular imaging procedure
- > 14 weeks of vedolizumab therapy + 15 mg vedolizumab-800CW group (Type: EXPERIMENTAL): Patients received 300mg vedolizumab + 15 mg vedolizumab-800CW after \>14 weeks vedolizumab therapy and subsequently underwent a Fluorescence molecular imaging procedure

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess the Long-term Safety of QVA149

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female adults aged ≥40 yrs~* Smoking history of at least 10 pack years~* Diagnosis of COPD (moderate-to-severe as classified by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guidelines, 2008)~* Post-bronchodilator FEV1 \< 80% and ≥ 30% of the predicted normal value and post-bronchodilator FEV1/FVC (forced vital capacity) \<70%~Exclusion Criteria:~* Patients who have had a respiratory tract infection within 4 weeks prior to Visit 1~* Patients with concomitant pulmonary disease~* Patients with a history of asthma~* Any patient with lung cancer or a history of lung cancer~* Patients with a history of certain cardiovascular co-morbid conditions~* Patients with a known history and diagnosis of alpha-1 antitrypsin deficiency~* Patients in the active phase of a supervised pulmonary rehabilitation program~* Patients contraindicated for inhaled anticholinergic agents and β2 agonists~* Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- QVA149 (Type: EXPERIMENTAL): 110µg/50µg capsule for oral inhalation, once daily, delivered by a single dose dry powder inhaler (SDDPI)
- Placebo (Type: PLACEBO_COMPARATOR): Placebo to match QVA149, capsules for inhalation once daily, delivered by an SDDPI

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dose-Escalation Study of ALXN1210 IV in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female ≥18 years of age~2. PNH diagnosis confirmed by documented high-sensitivity flow cytometry~3. Documented meningococcal vaccination not more than 3 years prior to dosing~4. Female participants of childbearing potential used highly effective contraception starting at screening and continuing until at least 24-weeks after the last dose of ALXN1210~5. Willing and able to give written informed consent and comply with the study visit schedule~Exclusion Criteria:~1. Treatment with a complement inhibitor at any time~2. Females who were pregnant, breastfeeding or who had a positive pregnancy test at screening or Day 1~3. Participation in an interventional clinical study within 30 days before initiation of dosing on Day 1, or use of any experimental therapy within 30 days prior to dosing on Day 1, or within 5 half-lives of the product, whichever is greater~4. History of allergy to excipients of ALXN1210 or known allergy to Chinese hamster ovary cell proteins~5. Inability to comply with study requirements~6. History of any clinically significant cardiac, hepatic, immunologic, pulmonary, or rheumatoid disease that, in the Investigator's judgment, would preclude participation~7. Other unspecified reasons that, in the opinion of the Investigator or Sponsor, made the participant unsuitable for enrollment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort 1 (Type: EXPERIMENTAL): Participants were administered ALXN1210 900 mg.~In the Extension period participants continued at the same dose and frequency as the Primary Evaluation Period.
- Cohort 2 (Type: EXPERIMENTAL): Participants were administered ALXN1210 1800 mg.~In the Extension period participants continued at the same dose and frequency as the Primary Evaluation Period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Local Infiltration Analgesia Following Unicompartmental Knee Arthroplasty

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients scheduled for unicompartmental knee arthroplasty~* Aged 20-80 yrs.~* ASA physical status I-III and mobility indicating normal postoperative mobilization~Exclusion Criteria:~* Known allergy or intolerance to one of the study drugs~* Serious liver-, heart- or renal decease~* Rheumatoid arthritis~* Chronic pain or bleeding disorder

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- A (Type: ACTIVE_COMPARATOR): Group A (Active) receives a multimodal injection intra- and postoperatively
- P (Type: PLACEBO_COMPARATOR): Group P (Placebo) receives no injection intraoperatively and a saline injection postoperatively

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Itopride in Functional Dyspepsia:a Dose Finding Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Diagnosis of functional dyspepsia (Rome criteria) -~Exclusion Criteria:~structural or biochemical abnormalities explaining the symptoms, concomitant symptoms of gastroesophageal reflux disease or irritable bowel syndrome dominating the clinical picture~-

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 95 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Empagliflozin on Liver Fat in Non-diabetic Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Potential study subjects will first be screened by transient elastography for the presence of hepatic steatosis (defined as a measurement of controlled attenuation parameter \[CAP\] \>= 248 db/M).~* They will be recruited into study if steatosis is \>= 5% as confirmed by MRI-PDFF~Exclusion Criteria:~* DM (defined as hemoglobin A1c \[HbA1c\] \>= 6.5% or fasting glucose \>= 7.0 mmol/L)~* alcohol intake \> 20g within past 2 years~* concurrent chronic liver diseases (including chronic viral hepatitis infection, autoimmune hepatitis, Wilson's disease, hemochromatosis, congestive hepatopathy, primary biliary cholangitis, primary sclerosing cholangitis, biliary tract obstruction)~* drug-induced liver disease~* usage of drugs that can lead to hepatic steatosis (e.g. steroids, amiodarone, valproate, methotrexate, tamoxifen)~* decompensated cirrhosis (including ascites, hepatic hydrothorax, variceal bleeding, hepatic encephalopathy, hepatorenal syndrome, hepatopulmonary syndrome)~* history of malignancy including HCC~* recreational substance abuse~* pregnancy~* contraindications to empagliflozin use (estimated glomerular filtration rate \[eGFR\] \<45mL/min/1.73m2 as measured by the MDRD equation, history of recurrent genitourinary tract infections, gangrene, or allergy)~* contraindications to MRI (e.g., claustrophobia, certain cardiac pacemakers, implanted medical devices with ferromagnetic properties).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Empagliflozin group (Type: EXPERIMENTAL): Empagliflozin 10mg daily for 52 weeks
- Placebo group (Type: PLACEBO_COMPARATOR): Placebo pills (identical in appearance to empagliflozin 10mg) daily for 52 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Oseltamivir Randomised Controlled Efficacy Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Persons at least one year old residing in randomly selected households with at least one major illness sign, or if absent at least two minor illness signs who are rapid test positive for either influenza A or influenza B.~Exclusion Criteria:~* Persons with a history of non-febrile convulsions or~* Persons who are taking anticonvulsive agents, or~* Persons who have a nonrespiratory comorbid condition requiring immediate medical intervention, or~* Persons who are pregnant.

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Oseltamivir for 5 days for patients with illness duration \< 48 hours
- 2 (Type: PLACEBO_COMPARATOR): Placebo for 5 days for patients with illness duration \< 48 hours
- 3 (Type: EXPERIMENTAL): Oseltamivir for 5 days for patients with illness duration ≥ 48 hours
- 4 (Type: PLACEBO_COMPARATOR): Placebo for 5 days for patients with illness duration ≥ 48 hours

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase I Study of LDK378 in Pediatric, Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with a locally advanced or metastatic malignancy that has progressed despite standard therapy, or for which no effective standard therapy exists~* Age ≥ 12 months and \< 18 years~* The tumor must carry a genetic alteration of ALK~* Patients must have evaluable or measurable disease.~* Karnofsky performance status score ≥ 60% for patients \> 12 years of age; Lansky score ≥ 50% for patients ≤ 12 years of age.~Exclusion criteria:~* Symptomatic central nervous system (CNS) metastases who are neurologically unstable or require increasing doses of steroids or local CNS-directed therapy (such as radiotherapy, surgery or intrathecal chemotherapy) to control their CNS disease~* Inadequate end organ function as defined by specified laboratory values~* Body surface area (BSA) \< 0.35 m2~* Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of LDK378 (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, or malabsorption syndrome)~* Use of medications that are known to be strong inhibitors or inducers of CYP3A4/5 that cannot be discontinued at least 1 week prior to start of treatment with LDK378 and for the duration of the study~* Use of medications that are mainly metabolized by CYP3A4/5 or CYP2C9 that cannot be discontinued at least 1 week prior to start of treatment with LDK378 and for the duration of the study~* History of interstitial lung disease or interstitial pneumonitis, including clinically significant radiation pneumonitis~* History of pancreatitis or history of increased amylase or lipase that was due to pancreatic disease.~* Medications with a known risk of prolongation of QT interval

- Gender: ALL
- Minimum Age: 12 Months
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- LDK378 (Type: EXPERIMENTAL): All participants were administered a single-agent LDK378 (Ceritinib) orally, once daily, continuously in fasted or fed conditions.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Accelerated Intermittent Theta Burst Stimulation for Depressive Symptoms

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Over 18 years old~* Able to read, understand, and provide written, dated informed consent prior to screening. Participants will be deemed likely to comply with study protocol and communicate with study personnel about adverse events and other clinically important information.~* Currently diagnosed with Major Depressive Disorder (MDD) and/or in a current major depressive episode, according to the criteria defined in the Diagnosis and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR)~* Currently an inpatient at Stanford Hospital~* Meet the threshold on the total HAMD17 score of \>/=20 at screening/baseline.~* Qualifies and has access to outpatient rTMS treatment~Exclusion Criteria:~* Any structural lesion e.g. structural neurological condition, more subcortical lesions than would be expected for age, stroke effecting stimulated area or connected areas or any other clinically significant abnormality that might affect safety, study participation, or confound interpretation of study results.~* Metal implant in brain (e.g. deep brain stimulation), cardiac pacemaker, or cochlear~* History of epilepsy/ seizures (including history of withdrawal/ provoked seizures)~* Shrapnel or any ferromagnetic item in the head~* Pregnancy~* Autism Spectrum disorder~* Active substance use (\<1 week) or intoxication verified by toxicology screen--of cocaine, amphetamines, benzodiazepines~* Any current or past history of any physical condition which in the investigator's opinion might put the subject at risk or interfere with study results interpretation~* Cognitive impairment (including dementia)~* Current severe insomnia (must sleep a minimum of 4 hours the night before stimulation)~* Current mania~* Current unmanageable psychosis~* IQ \<70~* Showing symptoms of withdrawal from alcohol or benzodiazepines~* Parkinsonism or other movement d/o determined by PI to interfere with treatment~* More subcortical lesions than would be expected for age or a stroke effecting stimulated area or connected areas.~* Any other indication the PI feels would comprise data.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Dorsolateral Prefrontal Cortex (Type: EXPERIMENTAL): The accelerated theta burst stimulation protocol will be applied to the left dorsolateral prefrontal cortex (L-DLPFC), for 10 sessions per day for up to 5 days.
- Anterior Cingulate Cortex (Type: EXPERIMENTAL): The accelerated theta burst stimulation protocol will be applied to the left anterior cingulate cortex (ACC), for 10 sessions per day for up to 5 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study in Adult and Adolescent Subjects With PAR (Perennial Allergic Rhinitis)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Informed Consent~* Documented history of perennial allergic rhinitis~* A demonstrated sensitivity to at least one allergen known to induce PAR through a standard skin prick test.~* Minimum subject-reported reflective total nasal symptom score (rTNSS) of at least 6 (out of a possible 12)~* Other criteria apply~Exclusion Criteria:~* History of physical findings of nasal pathology (within 60 days prior to screening visit)~* Participation in any investigational drug study 30 days preceding screening visit~* History of respiratory infection/disorder with 14 days preceding screening visit or during the run-in period~* Use of any prohibited concomitant medications

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BDP HFA 320 µg/day (Type: EXPERIMENTAL): During the 6-week double-blind Treatment Period participants self-administered 4 actuations (two per nostril) of 80 µg BDP HFA once daily.
- Placebo (Type: PLACEBO_COMPARATOR): During the 6-week double-blind Treatment Period participants self-administered four actuations (two per nostril) of placebo HFA once daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Gabapentin vs Chlordiazepoxide for Ambulatory Alcohol Withdrawal

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Alcohol dependent at risk for withdrawal symptoms~Exclusion Criteria:~* Benzodiazepine dependent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Chlordiazepoxide (Type: ACTIVE_COMPARATOR): Chlordiazepoxide 25mg capsule or matching placebo capsule
- Gabapentin (Type: EXPERIMENTAL): Gabapentin 300mg capsule or matching placebo capsule

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete